---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-003982"
form_type: "8-K"
ticker: "AIXC"
cik: "0001460702"
company_name: "AIxCrypto Holdings, Inc."
filed_at: "2025-01-28T23:59:59+00:00"
generated_at: "2026-05-27T08:14:53.819907+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Qualigen leads NanoSynex bridge round for rapid AST technology

## Summary
- Qualigen is first investor in NanoSynex's 2025 bridge round of up to $500K.
- NanoSynex's AST halves test time; global market projected at $4.7B by 2027.
- US AST market expected $1.6B; NanoSynex targets EU approval 2027, US 2028.
- NanoSynex holds 4 patents; product has competitive advantages and pipeline.
- CEO says investment supports better antibiotic use and robust diagnostics.

## SEC filing metadata
- accession: 0001493152-25-003982
- form_type: 8-K
- ticker: AIXC
- cik: 0001460702
- company_name: AIxCrypto Holdings, Inc.
- filed_at: 2025-01-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460702/000149315225003982/0001493152-25-003982-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460702/000149315225003982/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-003982
- JSON: https://secwatch.observer/filing/0001493152-25-003982.json
- Plain text: https://secwatch.observer/filing/0001493152-25-003982.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.